Skip to main content
OpenTrials
Completed

NCT Number: NCT04957082

Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake

This disparities-focused study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among African Americans residing in Flint, Michigan. This iteration will consider individuals recruited from the Flint Registry and assess willingness to participate in a drive-up saliva sample collection taking place at a central location in Flint, Michigan.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SARS-CoV2 Infection COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Flint Journal Building

Flint, Michigan, 48502, United States

About this study

African Americans develop and die from SARS-CoV-2 infection more than any other racial group in the United States, including in majority African American cities such as Flint, Michigan. Addressing these disparities may be aided by SARS-CoV-2 antibody testing. However, African Americans may be reluctant to partake in conventional antibody testing programs due to medical mistrust and experiences with racism. This study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing. The central hypothesis is that African-Americans will be more receptive to antibody testing when benefits and limitations are communicated in a culturally effective manner. Our clinical trial aims are to 1) develop and compare effects of a general versus culturally-targeted video about antibody testing on African American and White Flint residents' antibody testing attitudes and uptake; 2) identify and compare effects of a general versus culturally-targeted video on activation of medical mistrust and racism-related cognition among African Americans when considering antibody testing. In collaboration with clinical and community partners, we have prepared and will evaluate general and culturally-targeted video tutorials about SARS-CoV-2 antibody testing. These brief videos will be distributed to the Flint community through the Flint Registry - a highly visible local health resource exchange. We will furnish an opportunity to engage salivary antibody screening and measure willingness to participate. In this study iteration, we will consider willingness to participate in a drive-up saliva sample collection that is taking place at a central location in Flint, Michigan.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • African American or White, 18 or older, and enrolled in the Flint Registry

Exclusion criteria

  • All who do not meet inclusion criteria.

Treatment and study plan

Culturally Targeted SARS-CoV-2 Communication

Behavioral

SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.

General SARS-CoV-2 Communication

Behavioral

SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information

Primary outcomes

  1. Number (Percentage) of Participants Requested to Participate in Saliva-based SARS-CoV-2 Antibody Testing

    Time frame: Immediately following didactic study portion and health communication randomization on day 1.

    Number (Percentage) of participants who respond "yes" to be included in offer to participate in no cost SAR-CoV-2 salivary antibody test.

  2. Number (Percentage) of Participants Who Requested Saliva-based SARS-CoV-2 Antibody Testing Participated in the Testing.

    Time frame: 8 weeks from the day of consenting to participate in the salivary-based SARS-CoV-2 antibody testing

    Number (Percentage) of participants that requested to participate in antibody testing who actually complete antibody testing.

  3. SARS-CoV-2 Antibody Testing Attitudes

    Time frame: Immediately following didactic study portion and health communication randomization on day 1.

    Submeasure of Theory of Planned Behavior Indicating extent of a favorable attitude SARS-CoV-2 towards antibody testing (Seven point Likert Rating, with higher scores indicating more favorable Attitudes).

  4. SARS-CoV-2 Antibody Testing Normative Beliefs

    Time frame: Immediately following didactic study portion and health communication randomization on day 1.

    Sub-measure of Theory of Planned Behavior Indicating extent to which believes other people are favorable towards SARS-CoV-2 towards antibody testing (Seven point Likert Rating, with higher scores indicating stronger Normative Beliefs).

  5. Antibody Testing Perceived Behavioral Control

    Time frame: Immediately following didactic study portion and health communication randomization on day 1.

    Sub-measure of Theory of Planned Behavior Indicating Self Efficacy to Complete Antibody Testing (Seven point Likert Rating, with higher scores indicating greater Perceived Behavioral Control).

  6. Antibody Testing Intentions

    Time frame: Immediately following didactic study portion and health communication randomization on day 1.

    Sub-measure of Theory of Planned Behavior indicating Intentions to Complete Antibody Testing (Seven point Likert Rating, with higher scores indicating stronger screening Intentions).

  7. Antibody Testing Anticipatory Racism

    Time frame: Immediately following didactic study portion and health communication randomization on day 1.

    Extent to which participants believe that racism-related factors would diminish the value of SARS-CoV-2 antibody testing for self (Seven-point Likert rating, with higher scores indicating greater Anticipatory Racism).

Sponsors and collaborators

Lead sponsor

Michigan State University

Other

Collaborators

  • Johns Hopkins University
  • National Cancer Institute (NCI)

Registry information

Official study title

Culturally-targeted Communication to Promote SARS-CoV-2 Antibody Testing in Saliva: Enabling Evaluation of Inflammatory Pathways in COVID-19 Racial Disparities

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jul 12, 2021
Registry last updated
Jun 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.